Biocryst Pharmaceuticals (BCRX) Non-Current Debt (2011 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Non-Current Debt came in at $395.2 million in Q1 2026, up 25.3% YoY from $315.4 million in Q1 2025, and up 103.33% on a QoQ basis from $194.4 million in Q3 2025.
Biocryst Pharmaceuticals (BCRX) Non-Current Debt (2011 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 16 years of Non-Current Debt data on file, last reported at $395.2 million in Q1 2026.
- Quarterly Non-Current Debt rose 25.3% year-over-year to $395.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $395.2 million (up 25.3% YoY) and the FY2024 annual result came in at $314.9 million, up 3.84% from the prior year.
- Non-Current Debt grew to $395.2 million in Q1 2026, from $194.4 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $395.2 million in Q1 2026 to a low of $140.2 million in Q1 2022.
- A 5-year average of $266.7 million and a median of $295.6 million in 2023 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2023 — Non-Current Debt soared 102.87% — and 2025, when it slumped 38.17%.
- Tracing BCRX's Non-Current Debt over 5 years: stood at $231.6 million in 2022, then soared by 30.92% to $303.2 million in 2023, then gained by 3.84% to $314.9 million in 2024, then tumbled by 38.27% to $194.4 million in 2025, then jumped by 103.33% to $395.2 million in 2026.
- The last three Non-Current Debt figures came in at $395.2 million (Q1 2026), $194.4 million (Q3 2025), and $242.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 395.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 395.40 Mn |
| Mar 31, 2026 | 395.20 Mn |
| Sep 30, 2025 | 194.37 Mn |
| Jun 30, 2025 | 242.79 Mn |
| Mar 31, 2025 | 315.41 Mn |
| Dec 31, 2024 | 314.87 Mn |
| Sep 30, 2024 | 314.33 Mn |
| Jun 30, 2024 | 313.82 Mn |
| Mar 31, 2024 | 308.48 Mn |
| Dec 31, 2023 | 303.23 Mn |
| Sep 30, 2023 | 298.00 Mn |
| Jun 30, 2023 | 293.18 Mn |
| Mar 31, 2023 | 232.52 Mn |
| Dec 31, 2022 | 231.62 Mn |
| Sep 30, 2022 | 223.87 Mn |
| Jun 30, 2022 | 144.52 Mn |
| Mar 31, 2022 | 140.24 Mn |
| Dec 31, 2021 | 298.14 Mn |
| Sep 30, 2021 | 132.05 Mn |
| Jun 30, 2021 | 126.80 Mn |